Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart,
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline results
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Announced intent to file a biologics license application (BLA) for deramiocel to treat all patients with DMD-cardiomyopathy Rolling BLA
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2024 and highlighted recent and key upcoming expected milestones.
Sixers Wire17h
Hurricane forecast: Florida could see a rare and major threat or a sloppy system
In practical terms, it’s still October out there. The area to watch is a tropical wave merging with yet another Central ...
News4Jax1d
Tracking the Tropics: Florida could be seeing Sara soon. Here’s what you need to know
Currently, a tropical wave near Cuba is expected to interact with a low-pressure system in the southwestern Caribbean known ...
The Cool Down on MSN2d
Remote island trapped in 'vortex' of plastic — and they're not the ones to blame
Easter Island, also known as Rapa Nui by the locals, is a remote island off the coast of Chile. As of 2023, its population ...
ClimateConnections1d
Yet another November hurricane threat is taking shape
A named storm will likely form in the Northwest Caribbean later this week, and it could strengthen and head toward Florida or ...
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...
Nasdaq19d
Gyre Therapeutics Breaks Above 200-Day Moving Average - Bullish for GYRE
In trading on Friday, shares of Gyre Therapeutics Inc (Symbol: GYRE) crossed above their 200 day moving average of $14.43, changing hands as high as $14.83 per share. Gyre Therapeutics Inc ...
Hosted on MSN1mon
Impactful tropical threat could be brewing in Caribbean with potential track into Gulf of Mexico
The growing concern is linked to a phenomenon known as the Central American Gyre, which has historically contributed to tropical storm formation in the Caribbean or Gulf of Mexico in the early ...
Yahoo Finance8mon
Gyre Therapeutics, Inc. (GYRE)
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with ...
CNN10mon
Gyre Therapeutics Inc
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...